Evaluation of interleukin 13 polymorphisms in systemic sclerosis

Immunogenetics

Volumn 58, Issue 8, 2006, Pages 693-699

  Granel, Brigitte ^a,b   Chevillard, Christophe ^a   Allanore, Yannick ^c,i   Arnaud, Violaine ^a   Cabantous, Sandrine ^a   Marquet, Sandrine ^a   Weiller, Pierre Jean ^d   Durand, Jean Marc ^e   Harlé, Jean Robert ^e   Grange, Claire ^f   Frances, Yves ^b   Berbis, Philippe ^b   Gaudart, Jean ^g   De Micco, Philippe ^h   Kahan, André ^c   Dessein, Alain ^a  

^a INSERM   (France)

^b HÔPITAL NORD   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d TIMONE HOSPITAL   (France)

^e HÔPITAL DE LA CONCEPTION   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g CNRS   (France)

^h ETABLISSEMENT FRANÇAIS DU SANG   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Fibrosis; IL13 gene; Interleukin 13; Polymorphisms; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; INTERLEUKIN 13;

ADULT; AGED; ALLELE; ARTICLE; CAUCASIAN; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; EVALUATION; FEMALE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

EID: 33746239262     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00251-006-0135-0     Document Type: Article

References (28)

1. Artlett CM (2005) Immunology of systemic sclerosis. Front Biosci 10:170-719
2. Assassi S, Tan FK (2005) Genetics of scleroderma: update on single nucleotide polymorphism analysis and microarrays. Curr Opin Rheumatol 17:761-767
3. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA (1999) An IL13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 104:777-785
4. Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A, Dayer JM (2003) Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 48:2593-2604
5. Doucet C, BroutyBoye D, PottinClemenceau C, Canonica GW, Jasmin C, Azzarone B (1998a) Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest 101:2129-2139
6. Doucet C, BroutyBoye D, PottinClemenceau C, Jasmin C, Canonica GW, Azzarone B (1998b) IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int Immunol 10:1421-1433
7. Graves PE, Kabesch M, Halonen M, Holberg CJ, Baldini M, Fritzsch C, Weiland SK, Erickson RP, von Mutius E, Martinez FD (2000) A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. J Allergy Clin Immunol 105:506-513
8. Hancock A, Armstrong L, Gama R, Millar A (1998) Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 18:60-65
9. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin-4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 26:328-332
10. Hummelshoj T, Bodtger U, Datta P, Malling HJ, Oturai A, Poulsen LK, Ryder LP, Sorensen PS, Svejgaard E, Svejgaard A (2003) Association between an interleukin-13 promoter polymorphism and atopy. Eur J Immunogenet 30:355-359
11. Johnson RW, Tew MB, Arnett FC (2002) The genetics of systemic sclerosis. Curr Rheumatol Rep 4:99-107
12. Kissin EY, Korn JH (2003) Fibrosis in scleroderma. Rheum Dis Clin North Am 29:351-369
13. Kouriba B, Chevillard C, Bream JH, Argiro L, Dessein H, Arnaud V, Sangare L, Dabo A, Beavogui AH, Arama C, Traore HA, Doumbo O, Dessein A (2005) Analysis of the 5q31-q33 locus shows an association between IL13-1055C/T IL-13-591A/G polymorphisms and Schistosoma haematobium infections. J Immunol 174:6274-6281
14. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA (2001) Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 194:809-821
15. LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573-1576
16. Liu X, Nickel R, Beyer K, Wahn U, Ehrlich E, Freidhoff LR, Bjorksten B, Beaty TH, Huang SK (2000) An IL13 coding region variant is associated with a high total serum IgE level and atopic dermatitis in the German multicenter atopy study (MAS-90). J Allergy Clin Immunol 106:167-170
17. Ma B, Zhu Z, Homer RJ, Gerard C, Strieter R, Elias JA (2004) The C10/CCL6 chemokine and CCR1 play critical roles in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 172:1872-1881
18. Matsushita M, Yamamoto T, Nishioka K (2004) Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma. Int Arch Allergy Immunol 135:348-356
19. Ohshima K, Akaiwa M, Umeshita R, Suzumiya J, Izuhara K, Kikuchi M (2001) Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology 38:368-375
20. Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM (2000) Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 292:988-994
21. Riccieri V, Rinaldi T, Spadaro A, Scrivo R, Ceccarelli F, Franco MD, Taccari E, Valesini G (2003) Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol 22:102-106
22. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnosis and Therapeutic Criteria Committee (1980) Arthritis Rheum 23:581-590
23. Tolusso B, Fabris M, Caporali R, Cuomo G, Isola M, Soldano F, Montecucco C, Valentini G, Ferraccioli G (2005) -238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis. Immunol Lett 96:103-108
24. van der Pouw Kraan TC, van Veen A, Boeije LC, van Tuyl SA, de Groot ER, Stapel SO, Bakker A, Verweij CL, Aarden LA, van der Zee JS (1999) An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun 1:61-65
25. van der Pouw Kraan TC, Kucukaycan M, Bakker AM, Baggen JM, van der Zee JS, Dentener MA, Wouters EF, Verweij CL (2002) Chronic obstructive pulmonary disease is associated with the -1055 IL-13 promoter polymorphism. Genes Immun 3:436-439
26. Wills-Karp M, Chiaramonte M (2003) Interleukin-13 in asthma. Curr Opin Pulm Med 9:217
27. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA (1999) Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 103:779-788
28. Zhu Z, Ma B, Zheng T, Homer RJ, Lee CG, Charo IF, Noble P, Elias JA (2002) IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 168:2953-2962